Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
800 participants
OBSERVATIONAL
2008-06-30
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
NCT01894022
A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
NCT00578786
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
NCT04972656
Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg
NCT00687973
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
NCT00446563
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ambrisentan prescribed subjects
ambrisentan prescribed subjects
ambrisentan
ambrisentan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ambrisentan
ambrisentan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Darlinghurst, New South Wales, Australia
GSK Investigational Site
Chermside, Queensland, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Brussels, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Prague, , Czechia
GSK Investigational Site
Aarhus N, , Denmark
GSK Investigational Site
Besançon, , France
GSK Investigational Site
Bordeaux, , France
GSK Investigational Site
Brest, , France
GSK Investigational Site
Bron, , France
GSK Investigational Site
Caen, , France
GSK Investigational Site
Clamart, , France
GSK Investigational Site
Grenoble, , France
GSK Investigational Site
Lille, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Marseille, , France
GSK Investigational Site
Montpellier, , France
GSK Investigational Site
Nantes, , France
GSK Investigational Site
Pessac, , France
GSK Investigational Site
Poitiers, , France
GSK Investigational Site
Reims, , France
GSK Investigational Site
Rennes, , France
GSK Investigational Site
Rouen, , France
GSK Investigational Site
Strasbourg, , France
GSK Investigational Site
Toulouse, , France
GSK Investigational Site
Tours, , France
GSK Investigational Site
Vandœuvre-lès-Nancy, , France
GSK Investigational Site
Donaueschingen, Baden-Wurttemberg, Germany
GSK Investigational Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
GSK Investigational Site
Gerlingen, Baden-Wurttemberg, Germany
GSK Investigational Site
Heidelberg, Baden-Wurttemberg, Germany
GSK Investigational Site
Heidelberg, Baden-Wurttemberg, Germany
GSK Investigational Site
Löwenstein, Baden-Wurttemberg, Germany
GSK Investigational Site
Mannheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Ulm, Baden-Wurttemberg, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Regensburg, Bavaria, Germany
GSK Investigational Site
Cottbus, Brandenburg, Germany
GSK Investigational Site
Treuenbrietzen, Brandenburg, Germany
GSK Investigational Site
Hamburg, City state of Hamburg, Germany
GSK Investigational Site
Giessen, Hesse, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Greifswald, Mecklenburg-Vorpommern, Germany
GSK Investigational Site
Aachen, North Rhine-Westphalia, Germany
GSK Investigational Site
Cologne, North Rhine-Westphalia, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Moers, North Rhine-Westphalia, Germany
GSK Investigational Site
Solingen, North Rhine-Westphalia, Germany
GSK Investigational Site
Mainz, Rhineland-Palatinate, Germany
GSK Investigational Site
Dresden, Saxony, Germany
GSK Investigational Site
Leipzig, Saxony, Germany
GSK Investigational Site
Großhansdorf, Schleswig-Holstein, Germany
GSK Investigational Site
Lübeck, Schleswig-Holstein, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Alexandroupoli, , Greece
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Voula / Athens, , Greece
GSK Investigational Site
Napoli, Campania, Italy
GSK Investigational Site
Bologna, Emilia-Romagna, Italy
GSK Investigational Site
Rome, Lazio, Italy
GSK Investigational Site
Pavia, Lombardy, Italy
GSK Investigational Site
Orbassano (TO), Piedmont, Italy
GSK Investigational Site
Catania, Sicily, Italy
GSK Investigational Site
Palermo, Sicily, Italy
GSK Investigational Site
Florence, Tuscany, Italy
GSK Investigational Site
Pisa, Tuscany, Italy
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Amsterdam, , Netherlands
GSK Investigational Site
Groningen, , Netherlands
GSK Investigational Site
Maastricht, , Netherlands
GSK Investigational Site
Nieuwegein, , Netherlands
GSK Investigational Site
Nijmegen, , Netherlands
GSK Investigational Site
Rotterdam, , Netherlands
GSK Investigational Site
Bergen, , Norway
GSK Investigational Site
Oslo, , Norway
GSK Investigational Site
Bratislava, , Slovakia
GSK Investigational Site
Košice, , Slovakia
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Córdoba, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
Ourense, , Spain
GSK Investigational Site
Pontevedra, , Spain
GSK Investigational Site
Seville, , Spain
GSK Investigational Site
Toledo, , Spain
GSK Investigational Site
Valencia, , Spain
GSK Investigational Site
Gothenburg, , Sweden
GSK Investigational Site
Linköping, , Sweden
GSK Investigational Site
Lund, , Sweden
GSK Investigational Site
Umeå, , Sweden
GSK Investigational Site
Uppsala, , Sweden
GSK Investigational Site
Cambridge, , United Kingdom
GSK Investigational Site
Clydebank, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
London, , United Kingdom
GSK Investigational Site
Newcastle upon Tyne, , United Kingdom
GSK Investigational Site
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
110094
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.